Bariatric Surgery Demand Drops 20 Percent Following Anti-Obesity Drug Rollout in France
The introduction of specialized anti-obesity medications in French specialized centers has triggered a 20 percent reduction in the demand for bariatric surgery. France currently ranks as the third country globally for obesity operations, trailing behind Brazil and the United States, with approximately 40,000 surgical procedures performed annually following a peak of 60,000 procedures prior to the COVID-19 pandemic.
New Medical Referentials Position Drug Treatments Alongside Surgery
Official national guidelines do not yet exist for combining medical treatments with surgical interventions. However, the Coordination and Consultation Group of Specialized Obesity Centers and the FORCE research network have established a new clinical framework that defines three specific positions for candidates awaiting bariatric surgery.
In the first approach, anti-obesity medications are prescribed as neo-adjuvant therapy for a duration of six months to one year prior to surgery. This preparation targets patients with super obesity who present a body mass index exceeding 50, allowing them to lose weight and reduce surgical risks. In the second approach, treatments serve an adjuvant role for patients who fail to lose sufficient weight or experience weight regain one year following their operation. Clinicians avoid prescribing these medications during the first postoperative year due to risks of diarrhea and malnutrition driven by rapid weight loss. Finally, medications are offered as an alternative to surgery, ensuring all candidates receive informed consent regarding both options even though pharmacological weight loss remains lower than surgical outcomes.
Future Treatment Algorithms and Patient Inflow at Lyon South Hospital
Clinical algorithms do not yet exist to guide treatment selection for an average patient. While medications cannot match the rapid diabetes remission or massive weight loss delivered by surgery, clinical practice is set to shift within the next 18 months to two years with the arrival of a triple agonist drug capable of producing a 28 percent weight loss equivalent to a sleeve gastrectomy.
Emmanuel Disse, national coordinator of the FORCE clinical research network on obesity and head of the Endocrinology-Diabetology-Nutrition department at Lyon South Hospital, notes that expanded pharmacological access will ultimately drive more patients toward active obesity care who previously avoided surgical intervention. Data shows that after one year of treatment, a patient weighing 140 kilograms loses only 15 percent of their body weight on Wegovy and 20 percent on Mounjaro, leaving them eligible for subsequent surgery. Consequently, rising medication use will likely push annual bariatric surgical volumes well beyond 40,000 procedures.
The surge in public interest has created capacity strains. Following the announcement of reimbursement, the specialized obesity center at the Hospices Civils de Lyon received 15,000 telephone inquiries from across France. Despite expanding resources to accommodate 500 new patients each year, the clinic currently maintains a six-month waiting list for an initial appointment.
Frequently Asked Questions
How much weight do patients typically lose on anti-obesity medications compared to surgery?
Anti-obesity medications such as Wegovy and Mounjaro achieve weight loss of approximately 15 percent to 20 percent after one year in patients weighing around 140 kilograms, whereas upcoming triple agonist drugs are projected to reach a 28 percent weight loss equivalent to a sleeve gastrectomy.
Why are anti-obesity drugs withheld during the first year after bariatric surgery?
Clinicians do not prescribe these medications during the first postoperative year to prevent risks of diarrhea and a risk of malnutrition caused by rapid weight loss following the operation.
What is the current patient wait time at the Lyon South Hospital specialized obesity center?
Patients currently face a six-month delay for an initial appointment at the center operated by the Hospices Civils de Lyon, despite added capacity designed to intake 500 new patients annually.
Worth a look